Skip to Content

Notice

Memorandum of Understanding Between the United States Food and Drug Administration and the C-Path Institute

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between the United States Food and Drug Administration and the C-Path Institute. The specific purpose of this MOU is to establish an overarching framework for collaboration between the parties. This framework will be based on mutually agreed upon programs and activities in the areas of applied scientific research and training/education to foster the development of new evaluation tools to inform medical product development. The parties shall each leverage its own expertise and resources to facilitate programs of shared interests across the diverse disciplines of therapeutics, biological sciences, engineering and medical devices in building applied research and training/education programs. The appropriate formal agreements will be executed as required by law for any activities that result from this collaboration.

DATES:

The agreement became effective October 14, 2005.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

For C-Path Institute: Raymond L. Woosley, The Critical Path Institute, 4280 N. Campbell Ave., #214, Tucson, AZ 85718, 520-547-3440, FAX: 520-547-3456, e-mail: rwoosley@c-path.org.

For The Food and Drug Administration: Mary I. Poos, Office of External Relations, Food and Drug Administration (HF-10), 5600 Fishers Lane, Rockville, MD 20857, 301-827-2825, FAX: 301-827-3042, e-mail: mary.poos@fda.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the Federal Register, the agency is publishing notice of this MOU.

Start Signature

Dated: December 7, 2005.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature Start Printed Page 74824

Start Printed Page 74825

Start Printed Page 74826

Start Printed Page 74827 End Supplemental Information

BILLING CODE 4160-01-S

[FR Doc. 05-24100 Filed 12-15-05; 8:45 am]

BILLING CODE 4160-01-C